bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Free Report) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 708,000 shares, an increase of 17.3% from the July 15th total of 603,700 shares. Based on an average trading volume of 119,800 shares, the short-interest ratio is currently 5.9 days. Currently, 12.6% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
Separately, Maxim Group assumed coverage on bioAffinity Technologies in a research note on Tuesday, July 23rd. They set a “buy” rating and a $6.00 target price on the stock.
View Our Latest Research Report on BIAF
bioAffinity Technologies Stock Performance
bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($0.21) earnings per share for the quarter. bioAffinity Technologies had a negative return on equity of 134.34% and a negative net margin of 171.43%. The business had revenue of $2.41 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in bioAffinity Technologies stock. Ground Swell Capital LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned approximately 0.20% of bioAffinity Technologies at the end of the most recent quarter. 1.64% of the stock is currently owned by hedge funds and other institutional investors.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Further Reading
- Five stocks we like better than bioAffinity Technologies
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- This Small Cap Wealth Management Stock Could Provide Big Returns
- The 3 Best Retail Stocks to Shop for in August
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Are Growth Stocks and Investing in Them
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.